Stimulating Hematology Investigation: New Endeavors (SHINE) (R01 Clinical Trial Not Allowed)
ID: 337101Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/337101

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAS-22-096.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced the "Stimulating Hematology Investigation: New Endeavors (SHINE)" grant opportunity, aimed at fostering innovative research in nonmalignant hematology. This program invites investigator-initiated R01 grant applications focused on basic and early translational research in hematology, addressing critical areas such as blood cell development and the impact of aging on hematopoiesis. With an anticipated funding amount of approximately $2,150,000 for FY2022, the NIH plans to support 2-9 awards, with projects lasting up to five years. Interested applicants must adhere to strict submission guidelines and deadlines, with applications due by January 7, 2025. For further inquiries, contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov, and additional information can be found at the provided link: http://grants.nih.gov/grants/guide/pa-files/PAS-22-096.html.

    Point(s) of Contact
    OERWebmaster03@od.nih.gov
    Files
    Title
    Posted
    PAS-22-096-Full-Announcement.html
    PAS-22-096.html
    The Department of Health and Human Services (HHS) has issued a funding opportunity titled "Stimulating Hematology Investigation: New Endeavors (SHINE)" aimed at promoting innovative research in nonmalignant hematology. The program, supported by the National Institutes of Health (NIH) through multiple institutes including the NIDDK, NIA, and NHLBI, invites R01 grant applications focused on basic and early translational hematology research. Emphasizing dynamic research topics that will evolve over time, SHINE aims to close knowledge gaps in areas such as blood cell development and the effects of aging on hematopoiesis. Applications are due at various cycles, with a total funding of approximately $2,150,000 anticipated for FY2022, supporting 2-9 awards. The scope of projects can extend up to five years, and applicants must follow strict submission guidelines, including prior registrations with necessary agencies. The competitive selection process emphasizes scientific merit and relevance to program priorities, with detailed evaluation criteria set forth for the review process. The document outlines requirements for eligibility, application instructions, review information, and administrative guidelines, aiming to foster high-impact research within the hematology community.
    Similar Opportunities
    Stimulating Hematology Investigation: New Endeavors (SHINE) (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Stimulating Hematology Investigation: New Endeavors (SHINE)" aimed at promoting innovative research in non-malignant hematology. This initiative invites investigator-initiated research project grant applications (R01) that focus on basic and early translational hematology research, with a particular emphasis on fostering diverse perspectives within research teams through a required Plan for Enhancing Diverse Perspectives (PEDP). Approximately $2.5 million is available for 5-8 awards, with applications due by February 5, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Notice of Intent to Publish a Funding Opportunity Announcement for Continuation of the NIDDK Hematology Central Coordinating Center (U24 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) for the continuation of the NIDDK Hematology Central Coordinating Center (HCC) under a cooperative agreement. The HCC will collaborate with up to five Cooperative Centers of Excellence in Hematology (CCEH) to provide administrative support, develop communication strategies, and implement educational programs aimed at enhancing research in nonmalignant hematology. This initiative is crucial for fostering a national multidisciplinary research effort to study hematopoiesis and address nonmalignant hematologic diseases. The estimated total program funding is $1 million, with a single award anticipated, and the NOFO is expected to be published in December 2024, with applications due by March 2025. For further details, potential applicants should prepare to submit their proposals in alignment with the requirements outlined in the forthcoming NOFO.
    Limited Competition: Physician Scientist Transition to Independence in Blood Science Research (R00 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through its National Heart, Lung, and Blood Institute (NHLBI), has announced a Limited Competition Funding Opportunity titled "Physician Scientist Transition to Independence in Blood Science Research" (R00 - Clinical Trial Optional). This initiative aims to support the transition of outstanding blood science researchers with clinical doctorate degrees from mentored research positions to independent faculty roles, providing up to three years of funding for innovative research in blood science. The program is particularly focused on enhancing the scientific workforce by promoting diversity and fostering independent research careers that address critical health challenges in hematology. Interested applicants must submit their proposals by March 28, 2025, with a total funding ceiling of $250,000 available for new awards, and can direct inquiries to grantsinfo@nih.gov for further information.
    Continuation of the NIDDK Hematology Central Coordinating Center (U24 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the continuation of the NIDDK Hematology Central Coordinating Center (HCCC) through a cooperative agreement, aimed at enhancing collaboration among up to five Cooperative Centers of Excellence in Hematology. The HCCC will provide essential administrative and communication support, manage a Pilot and Feasibility Program, and promote research addressing nonmalignant hematologic diseases and normal hematopoiesis. This initiative is crucial for invigorating the field of hematology, fostering partnerships, and ensuring diverse perspectives in research teams. Interested applicants can find more information and apply by March 18, 2025, with an estimated funding amount of up to $1,000,000. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-25-023.html.
    Catalytic Tool and Technology Development in Kidney, Urologic, and Hematologic Diseases (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Catalytic Tool and Technology Development in Kidney, Urologic, and Hematologic Diseases (R21 Clinical Trial Not Allowed)." This initiative aims to support the development of innovative tools and technologies that address significant challenges in kidney, urologic, and hematologic research, encouraging high-risk, exploratory projects that differ from traditional R01 grants. The funding, with a maximum budget of $275,000 over two years, is open to a diverse range of eligible applicants, including various educational institutions and community organizations, with applications due by January 7, 2025. For further details, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-23-119.html.
    Investigator-Initiated Research in Genomics and Health Equity (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Investigator-Initiated Research in Genomics and Health Equity" (RFA-HG-23-017), aimed at promoting health equity through innovative genomic research. This initiative encourages applicants to propose research that enhances the understanding and application of genomics across diverse U.S. populations, with a particular focus on engaging underrepresented groups and incorporating a Plan for Enhancing Diverse Perspectives (PEDP). The NIH plans to commit significant funds, with a maximum budget of $500,000 in direct costs per year for projects lasting four to five years, and applications are due by July 8, 2025. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and are encouraged to review the full announcement at NIH Grants.
    Advancing Genomic Medicine Research (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Advancing Genomic Medicine Research (R21 Clinical Trial Optional)" aimed at stimulating innovation in the application of genomic information in clinical care, particularly for populations experiencing health disparities. The initiative seeks to enhance understanding of how to effectively implement and share genomic technologies across diverse communities, including racial and ethnic minorities, underserved rural populations, and sexual and gender minority groups. With an expected total funding of approximately $1.5 million for fiscal year 2024, individual project budgets may reach up to $250,000. Interested applicants must submit their proposals by February 11, 2025, and can find additional details and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Advancing Genomic Medicine Research (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Advancing Genomic Medicine Research (R21 Clinical Trial Optional)" aimed at stimulating innovative research in the integration of genomic information into clinical care, particularly for populations experiencing health disparities. This initiative encourages proposals that address implementation science, barriers to genomic medicine, and the integration of genomic data with health and social determinants, with a focus on enhancing health equity among underrepresented groups. The grant provides funding up to $250,000, with applications open from November 1, 2023, until the close date of February 11, 2025. Interested applicants can find more information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Advancing Genomic Medicine Research (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting proposals for the "Advancing Genomic Medicine Research (R01 Clinical Trial Optional)" grant, aimed at stimulating innovative research in the implementation of genomic technologies in clinical care. This funding opportunity emphasizes addressing health disparities and requires applicants to develop a Plan for Enhancing Diverse Perspectives to ensure inclusivity in research teams and participant recruitment. The initiative seeks to explore the value of genomic data in improving clinical outcomes, identify barriers to implementation, and develop effective data-sharing methods, with approximately $2.4 million available for three awards and an additional $700,000 for one award in fiscal year 2024. Applications are due by February 12, 2025, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Advancing Genomic Medicine Research (R03 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Advancing Genomic Medicine Research (R03 Clinical Trial Not Allowed)" aimed at stimulating innovation in the implementation and sharing of genomic information in clinical care across diverse populations. This initiative seeks proposals that enhance understanding of genomic data applications, assess implementation methods, and identify barriers to health equity, particularly for underrepresented groups. The R03 grant mechanism supports small research projects with a maximum budget of $50,000 per year, with an estimated total funding of approximately $150,000 for two awards in fiscal year 2024. Applications must be submitted electronically by February 12, 2025, and interested parties can contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.